Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SCL003
MIFTS: 48

Social Phobia

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Social Phobia

About this section

MalaCards integrated aliases for Social Phobia:

Name: Social Phobia 12 15
Phobia, Social 43 71
Phobic Anxiety Disorder 71
Phobia Social 54

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:11257
ICD9CM 34 300.23
MeSH 43 D000072861
NCIt 49 C34927
SNOMED-CT 67 25501002
UMLS 71 C0031572 C0349231
Sources

Summaries for Social Phobia

About this section
Disease Ontology : 12 A phobic disorder that involves social anxiety occurring only in specific public or social situations, interactions with others or being evaluated or scrutinized by other people.

MalaCards based summary : Social Phobia, also known as phobia, social, is related to depression and avoidant personality disorder. An important gene associated with Social Phobia is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Vortioxetine and Paroxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and amygdala, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Social Phobia

About this section

Diseases related to Social Phobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 depression 31.8 SLC6A4 MAOA HTR1A
2 avoidant personality disorder 31.4 WASF2 WASF1 SLC6A4 MAOA DRD2
3 generalized anxiety disorder 31.2 SLC6A4 MAOA HTR3A HTR1A DRD2 COMT
4 personality disorder 31.0 SLC6A4 PRL MAOA HTR3A HTR1A DRD2
5 eating disorder 31.0 SLC6A4 DRD2 COMT CCK
6 neurotic disorder 30.9 SLC6A4 MAOA HTR1A
7 delusional disorder 30.7 PRODH HTR1A DRD2
8 drug dependence 30.7 SLC6A4 HTR3A DRD2
9 panic disorder 30.7 TACR1 SLC6A4 PTK7 PRL MAOA HTR3A
10 atypical depressive disorder 30.7 SLC6A4 SERPINA3 MAOA HTR1A
11 separation anxiety disorder 30.6 WASF2 WASF1 SLC6A4 NBAS
12 sexual disorder 30.6 SLC6A4 PRL OXT HTR3A HTR1A DRD2
13 obsessive-compulsive personality disorder 30.5 WASF2 WASF1 SLC6A4
14 bruxism 30.5 SLC6A4 HTR1A DRD2
15 mood disorder 30.4 TACR1 SLC6A4 PRODH MAOA HTR3A HTR1A
16 hypochondriasis 30.4 SLC6A4 IVL HTR3A HTR1A
17 dependent personality disorder 30.4 WASF2 WASF1
18 major depressive disorder 30.4 TACR1 SLC6A4 PRL OXT MAOA HTR3A
19 dysthymic disorder 30.3 WASF2 WASF1 SLC6A4 MAOA IVL HTR1A
20 cocaine dependence 30.3 SLC6A4 PRL DRD2 COMT
21 somatization disorder 30.3 SLC6A4 OXT IVL HTR1A
22 schizophreniform disorder 30.2 PRODH PRL DRD2 COMT
23 fragile x syndrome 30.2 SLC6A4 PRODH MAOA LOC110806262
24 conduct disorder 30.2 SLC6A4 NBAS MAOA DRD2 COMT
25 obsessive-compulsive disorder 30.2 SLC6A4 PTK7 PRL OXT MAOA HTR3A
26 premature ejaculation 30.2 SLC6A4 OXT LOC110806262 HTR3A HTR1A COMT
27 alcohol use disorder 30.1 WASF2 WASF1 SLC6A4 PRODH HTR3A HTR1A
28 post-traumatic stress disorder 30.1 SLC6A4 MAOA DRD2 COMT CAT
29 anxiety 30.1 SLC6A4 PTK7 PRODH PRL OXT MIR485
30 alcohol dependence 30.1 TACR1 SLC6A4 PRL OXT MAOA HTR3A
31 alexithymia 30.0 SLC6A4 OXT LOC110806262 HTR1A DRD2 COMT
32 gilles de la tourette syndrome 29.9 SLC6A4 MAOA HTR3A HTR1A DRD2 COMT
33 oppositional defiant disorder 29.9 WASF2 WASF1 SLC6A4 MAOA DRD2 COMT
34 substance dependence 29.9 WASF2 WASF1 SLC6A4 MAOA DRD2 COMT
35 endogenous depression 29.9 TACR1 SLC6A4 OXT MAOA HTR3A HTR1A
36 anorexia nervosa 29.9 SLC6A4 PRL OXT MAOA HTR1A COMT
37 impulse control disorder 29.8 WASF1 SLC6A4 MAOA HTR1A DRD2 COMT
38 schizoaffective disorder 29.8 SLC6A4 PRODH PRL HTR1A DRD2 COMT
39 borderline personality disorder 29.8 SLC6A4 PRL MAOA HTR3A HTR1A DRD2
40 bipolar disorder 29.7 TACR1 SLC6A4 PRODH PRL MAOA HTR3A
41 agoraphobia 29.7 WASF2 WASF1 SLC6A4 PTK7 NBAS MAOA
42 schizotypal personality disorder 29.7 WASF2 WASF1 PRODH DRD2 COMT
43 substance abuse 29.6 WASF2 WASF1 SLC6A4 SERPINA3 PRODH PRL
44 autism 29.6 SLC6A4 PRODH PRL OXT MAOA HTR3A
45 bulimia nervosa 29.5 SLC6A4 PRL OXT MAOA HTR3A DRD2
46 autism spectrum disorder 29.5 SLC6A4 PRODH OXT MAOA DRD2 COMT
47 attention deficit-hyperactivity disorder 29.5 TACR1 SLC6A4 PRODH PRL OXT MAOA
48 mental depression 29.5 WASF2 WASF1 SLC6A4 SERPINA3 PRODH OXT
49 phobia, specific 29.1 WASF2 WASF1 SLC6A4 SERPINA3 PRODH NBAS
50 schizophrenia 29.0 SLC6A4 SERPINA3 PRODH PRL OXT MAOA

Comorbidity relations with Social Phobia via Phenotypic Disease Network (PDN):


Anxiety Dysthymic Disorder

Graphical network of the top 20 diseases related to Social Phobia:



Diseases related to Social Phobia
Sources

Symptoms & Phenotypes for Social Phobia

About this section

GenomeRNAi Phenotypes related to Social Phobia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Social Phobia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 COMT DRD2 HTR1A HTR3A MAOA NBAS
2 cardiovascular system MP:0005385 9.85 COMT DRD2 HTR1A MAOA NBAS OXT
3 homeostasis/metabolism MP:0005376 9.8 CAT CCK COMT DRD2 HTR1A HTR3A
4 nervous system MP:0003631 9.5 CCK COMT DRD2 HTR1A HTR3A MAOA
Sources

Drugs & Therapeutics for Social Phobia

About this section

Drugs for Social Phobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
2
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
3
Norepinephrine Approved Phase 4 51-41-2 439260
4
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
5
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
6
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
7
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
8
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
9
Topiramate Approved Phase 4 97240-79-4 5284627
10
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
11
Citalopram Approved Phase 4 59729-33-8 2771
12
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
13
Propranolol Approved, Investigational Phase 4 525-66-6 4946
14
Sertraline Approved Phase 4 79617-96-2 68617
15
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
16 Serotonin 5-HT3 Receptor Antagonists Phase 4
17 Cytochrome P-450 Enzyme Inhibitors Phase 4
18 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
19 Anticonvulsants Phase 4
20 Anti-Anxiety Agents Phase 4
21 Tranquilizing Agents Phase 4
22 Serotonin 5-HT1 Receptor Agonists Phase 4
23 Serotonin Antagonists Phase 4
24 Serotonin Receptor Agonists Phase 4
25 Serotonin 5-HT2 Receptor Antagonists Phase 4
26 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
27 Desvenlafaxine Succinate Phase 4 386750-22-7
28 Antipsychotic Agents Phase 4
29 Quetiapine Fumarate Phase 4 111974-72-2
30 GABA Agents Phase 4
31 GABA Modulators Phase 4
32 Atomoxetine Hydrochloride Phase 4
33 Venlafaxine Hydrochloride Phase 4
34 Dopamine Antagonists Phase 4
35 Dopamine D2 Receptor Antagonists Phase 4
36 Dopamine agonists Phase 4
37 Neuroprotective Agents Phase 4
38 Protective Agents Phase 4
39 Excitatory Amino Acid Antagonists Phase 4
40 Excitatory Amino Acids Phase 4
41 Hypoglycemic Agents Phase 4
42 Autonomic Agents Phase 4
43 Dopamine Agents Phase 4
44 Muscarinic Antagonists Phase 4
45 Parasympatholytics Phase 4
46 Cholinergic Antagonists Phase 4
47 Antiparkinson Agents Phase 4
48 Dopamine Uptake Inhibitors Phase 4
49 Central Nervous System Stimulants Phase 4
50 Antihypertensive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 286)
# Name Status NCT ID Phase Drugs
1 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
2 Nefazodone in the Treatment of Social Phobia: Functional Brain Imaging and Neuroendocrine Correlates Completed NCT00231348 Phase 4 Nefazodone
3 A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Pristiq® (Desvenlafaxine) Extended-Release Tablets in Generalized Social Anxiety Disorder Completed NCT01316302 Phase 4 Pristiq;Placebo
4 The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Effects on Cue Reactivity in Response to Virtual Reality Public Speaking Environment Completed NCT00407199 Phase 4 quetiapine
5 Improving Outcomes in Pharmacotherapy of Social Phobia Completed NCT00282828 Phase 4 Sertraline;Venlafaxine;Placebo;Clonazepam
6 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
7 Phase IV Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder Completed NCT00190879 Phase 4 Atomoxetine hydrochloride;placebo
8 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
9 Efficacy and Safety of Escitalopram in Patients With Social Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia Completed NCT00902226 Phase 4 Escitalopram
10 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
11 A 12-Week Open-Label Study Followed By A 24-Week Double-Blind Discontinuation Exploratory Study To Evaluate The Effects Of Gabitrilâ„¢ (Tiagabine Hydrochloride) In Patients With Social Anxiety Disorder (SAD) Completed NCT00208741 Phase 4 Gabitril
12 A Double-Blind, Placebo-Controlled, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Completed NCT01224067 Phase 4 Quetiapine
13 Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes Completed NCT00347269 Phase 4 Psychotropic medication optimization
14 The Use of Acamprosate in Individuals With Alcohol Dependence and Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
15 A Randomised, Triple Blind, Placebo-controlled Trial Comparing the Effects of Cognitive Therapy, Paroxetine and Both Cognitive Therapy and Paroxetine in the Treatment of Patients With Primary Social Phobia Completed NCT00184106 Phase 4 Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
16 Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay Completed NCT00895752 Phase 4 Riluzole
17 Topiramate Augmentation to a Selective Serotonin Re-uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo -Controlled Trial. Recruiting NCT00182455 Phase 4 Topiramate;Placebo
18 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
19 Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety Recruiting NCT03522844 Phase 4 Escitalopram
20 Brief Intervention to Reduce Fear of Public Speaking Active, not recruiting NCT02790736 Phase 4 propranolol;Placebo
21 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
22 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Social Anxiety Disorder (SAD) Terminated NCT03078270 Phase 4 botulinum toxin A
23 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice (SophoPrax) Unknown status NCT01388231 Phase 2, Phase 3
24 Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder Unknown status NCT03017508 Phase 2, Phase 3 BHV-0223;Placebo
25 Comparative Study of the Efficacy of a Cognitive-Behavioral Therapy for Post-Traumatic Stress Disorder With or Without D-Cycloserine Unknown status NCT00452231 Phase 2, Phase 3 D-cycloserine
26 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-term Study- <Phase III Study> Completed NCT00264654 Phase 3 BRL29060A;paroxetine hydrochloride hydrate
27 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Double-blind, Placebo-controlled Study- <Phase III Study> Completed NCT00318669 Phase 3 Paroxetine hydrochloride hydrate
28 Residential Cognitive Therapy Versus Residential Interpersonal Therapy for Social Phobia: A Randomized Controlled Trial Completed NCT00326430 Phase 2, Phase 3
29 A Randomized, Controlled Study of a Stepped-care Model for the Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
30 Treatment of Childhood Social Phobia Completed NCT00043537 Phase 3 Fluoxetine;Pill Placebo
31 A Comparison Between Internet-based Self-help Therapy and Group Therapy for Social Phobia - A Clinical Equivalence Trial Using Cognitive Behavioural Therapy (CBT) Completed NCT00564967 Phase 3
32 Placebo-Controlled Evaluation of the Efficacy of Yohimbine Hydrochloride for Enhancing the Effects of CBT for Social Phobia Completed NCT00958880 Phase 3 Yohimbine Hydrochloride;Sugar Pill
33 Double Blind Placebo Controlled Parallel Group Comparison of Atomoxetine (Strattera) for Generalized Social Anxiety Disorder (GSAD) Completed NCT00260533 Phase 2, Phase 3 atomoxetine;placebo
34 Placebo-Controlled Trial of Hypericum Perforatum in the Treatment of Generalized Social Anxiety Disorder (GSAD) Completed NCT00118833 Phase 2, Phase 3 Hypericum perforatum (St. John's wort)
35 A Single-center, Randomized, Double-blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (Oral Extended Release Tablets) to Placebo in Social Phobia Patients and Changes in Their Vasodilatory Response to Methyl-Nicotinate Completed NCT00773162 Phase 3 Seroquel;Sugar Pill
36 Research Unit on Pediatric Psychopharmacology Anxiety Treatment Study Completed NCT00000389 Phase 3 Fluvoxamine
37 D-cycloserine Enhancement of Exposure in Social Phobia Completed NCT00515879 Phase 3 D-cycloserine;Placebo
38 Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome Completed NCT00114127 Phase 3 Duloxetine;Duloxetine;Placebo
39 A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine ER In Children and Adolescent Outpatients With Social Anxiety Disorder Completed NCT00238719 Phase 3 Venlafaxine ER
40 2/3 Treatment of Anxiety in Autism Spectrum Disorder Completed NCT02028247 Phase 3
41 CBT Augmentation of Paroxetine for Social Anxiety Completed NCT00074802 Phase 3 Paroxetine
42 A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Quetiapine in Social Anxiety Disorder Completed NCT00215254 Phase 2, Phase 3 quetiapine
43 A Feasibility Study for a Phase 3, Randomized, Four-Week, Double-Blind, Placebo-Controlled, Crossover Trial of the Efficacy and Safety of PH94B Nasal Spray in the Acute Treatment of Social Anxiety Disorder (SAD) Completed NCT02622958 Phase 3 PH94B
44 Utilizing Health Information Technology to Improve Health Care Quality: Implementation of a Computerized Cognitive Behavioral Therapy Protocol for Childhood Anxiety Completed NCT01416805 Phase 3
45 Child/Adolescent Anxiety Multimodal Treatment Study Completed NCT00052078 Phase 3 Sertraline (SRT);Placebo
46 A Systems Level Intervention for Unemployed Persons With Social Anxiety Completed NCT01654510 Phase 2, Phase 3
47 A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder (GAD) or Social Anxiety Disorder (SAD), Who Are Only Partial Responders to Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRI's) or Selective Serotonin Reuptake Inhibitors (SSRI's). Completed NCT00411398 Phase 3 Namenda/Memantine
48 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Completed NCT01178385 Phase 2, Phase 3
49 A Randomized Controlled Trial of Multimodal Music Therapy for Children With Anxiety Disorders Completed NCT01062646 Phase 3
50 Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Not yet recruiting NCT03549819 Phase 3 Cannabidiol (CBD) Oil Capsules;Sunflower Lecithin Oil in Capsule

Search NIH Clinical Center for Social Phobia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


gabapentin
gabapentin enacarbil
Paroxetine
Paroxetine Hydrochloride

Cochrane evidence based reviews: phobia, social

Sources

Genetic Tests for Social Phobia

About this section
Sources

Anatomical Context for Social Phobia

About this section

MalaCards organs/tissues related to Social Phobia:

40
Brain, Testes, Amygdala, Cortex, Heart, Eye, Prefrontal Cortex
Sources

Publications for Social Phobia

About this section

Articles related to Social Phobia:

(show top 50) (show all 3722)
# Title Authors PMID Year
1
Association of COMT (Val158Met) and BDNF (Val66Met) gene polymorphisms with anxiety, ADHD and tics in children with autism spectrum disorder. 54 61
19582565 2009
2
Impact of prosocial neuropeptides on human brain function. 54 61
18655902 2008
3
Stimuli and consequences of dendritic release of oxytocin within the brain. 54 61
17956324 2007
4
The neuroscience of affiliation: forging links between basic and clinical research on neuropeptides and social behavior. 54 61
16884725 2006
5
Oxytocin modulates neural circuitry for social cognition and fear in humans. 54 61
16339042 2005
6
[Neurobiology and pharmacotherapy of social phobia]. 54 61
15538306 2004
7
Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. 54 61
15158011 2004
8
Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652. 54 61
12457263 2002
9
A preliminary study of dopamine-mediated prolactin inhibition in generalised social phobia. 54 61
12140123 2002
10
Social phobia: diagnosis, severity and implications for treatment. 54 61
10361959 1999
11
Genetic linkage to the serotonin transporter protein and 5HT2A receptor genes excluded in generalized social phobia. 54 61
9925179 1998
12
Placebo-controlled trial of moclobemide in social phobia. 54 61
9534836 1998
13
Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. 54 61
9397424 1997
14
Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. 54 61
8619339 1995
15
[3H]paroxetine binding to platelets of patients with social phobia: comparison to patients with panic disorder and healthy volunteers. 54 61
7711158 1995
16
Reversible monoamine oxidase-A inhibitors in social phobia. 54 61
8313403 1993
17
School-Based Treatment for Anxiety Research Study (STARS): a Randomized Controlled Effectiveness Trial. 61
31749064 2020
18
Dissociative symptoms as measured by the Cambridge Depersonalization Scale in patients with a bipolar disorder. 61
31818776 2020
19
Developing algorithms to predict adult onset internalizing disorders: An ensemble learning approach. 61
31864158 2020
20
Childhood maltreatment, anxiety disorders and outcome in borderline personality disorder. 61
31784066 2020
21
The Impact of Treatment Expectations on Exposure Process and Treatment Outcome in Childhood Anxiety Disorders. 61
31313062 2020
22
The longitudinal course of pregnancy-related anxiety in parous and nulliparous women and its association with symptoms of social and generalized anxiety. 61
31494362 2020
23
Feasibility and Pilot Efficacy Testing of Integrated Yoga and Shirodhara (Ayurvedic Oil-Dripping) Intervention on Clinical Symptoms, Cognitive Functions and Sleep Quality of Adults with Anxiety Disorder. 61
32030019 2020
24
Comorbidity with more anxiety disorders associated with a poorer prognosis persisting at the 10-year follow-up among patients with major depressive disorder. 61
31493646 2020
25
Social phobia in immune-mediated inflammatory diseases. 61
31816595 2020
26
Mental disorders in adolescents, youth, and adults in the RPS Birth Cohort Consortium (Ribeirão Preto, Pelotas and São Luís), Brazil. 61
32022176 2020
27
Effectiveness and Cost-Effectiveness of a Self-Guided Internet Intervention for Social Anxiety Symptoms in a General Population Sample: Randomized Controlled Trial. 61
31821151 2020
28
Prospective Analysis and Comparison of Periareolar Excision (Delivery) Technique and Pull-Through Technique for the Treatment of Gynecomastia. 61
31989232 2020
29
Variations in psychiatric morbidity between traumatized Norwegian, refugees and other immigrant patients in Oslo. 61
31961250 2020
30
Role of Benzodiazepines in Anxiety Disorders. 61
32002938 2020
31
Social phobia moderates the outcome in the EVIDENT study: A randomized controlled trial on an Internet-based psychological intervention for mild to moderate depressive symptoms. 61
31682137 2020
32
Social anxiety disorder among patients with multiple sclerosis: a population-based case-control study in Ecuador. 61
31930470 2020
33
Anxiety disorders comorbidity in pediatric bipolar disorder: a meta-analysis and meta-regression study. 61
31899546 2020
34
The effect of anticipatory stress and openness and engagement on subsequently perceived sleep quality-An Experience Sampling Method study. 61
31850590 2019
35
Trait anger and anger attacks in relation to depressive and anxiety disorders. 61
31450135 2019
36
Factors associated with social anxiety in South Korean adults with epilepsy. 61
31675602 2019
37
Higher social rejection sensitivity in opioid-dependent patients is related to smaller insula gray matter volume: A voxel-based morphometric study. 61
31820807 2019
38
Association between medicated obstructive pulmonary disease, depression and subjective health: results from the population-based Gutenberg Health Study. 61
31882715 2019
39
Anxiety disorders in outpatient clinics of epilepsy in tertiary care hospitals: A meta-analysis. 61
31874357 2019
40
Video games use in childhood and adolescence: Social phobia and differential susceptibility to media effects. 61
31674805 2019
41
The Role of Traumatic Experiences and Posttraumatic Stress on Social Anxiety in a Youth Sample in Lithuania. 61
31773470 2019
42
Prevalence, correlates and comorbidities of feeding and eating disorders in a nationally representative sample of Iranian children and adolescents. 61
31742760 2019
43
Modulation of the Endocannabinoid and Oxytocinergic Systems as a Potential Treatment Approach for Social Anxiety Disorder. 61
31617149 2019
44
Anxiety in Early Adolescence: Heterogeneous Developmental Trajectories, Associations with Risk Factors and Depressive Symptoms. 61
31630311 2019
45
General or specific? The memory-experience gap for individuals diagnosed with a major depressive disorder or a social phobia diagnosis, and individuals without such diagnoses. 61
31311430 2019
46
Resting respiratory sinus arrhythmia moderates the association between social phobia symptoms and self-reported physical symptoms. 61
31276300 2019
47
Associations between adolescent social phobia, sickness absence and unemployment: a prospective study of twins in Sweden. 61
30879025 2019
48
Development and validation of the Premorbid Childhood Traits Questionnaire (PCT-Q) in eating disorders. 61
31313252 2019
49
Prevalence and features of spontaneous recurrent images in social anxiety disorder: findings from a Korean community sample. 61
31647048 2019
50
Transition memories: experiences of trans adult women with hormone therapy and their beliefs on the usage of hormone blockers to suppress puberty. 61
30953318 2019
Sources

Variations for Social Phobia

About this section
Sources

Expression for Social Phobia

About this section
Search GEO for disease gene expression data for Social Phobia.
Sources

Pathways for Social Phobia

About this section

Pathways related to Social Phobia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.76 TACR1 SLC6A4 MAOA HTR3A HTR1A
2
Serotonergic synapse 36
11.68 SLC6A4 MAOA HTR3A HTR1A
3
Neurotransmitter Clearance In The Synaptic Cleft 65
Show member pathways
 10.85 SLC6A4 MAOA COMT
4
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
10.7 SLC6A4 MAOA HTR3A HTR1A
5
noradrenaline and adrenaline degradation 1
Show member pathways
 10.58 MAOA COMT
6
Dopamine metabolism 1
10.51 MAOA COMT
7
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.38 SLC6A4 MAOA HTR1A DRD2 COMT
Sources

GO Terms for Social Phobia

About this section

Cellular components related to Social Phobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SCAR complex GO:0031209 9.16 WASF2 WASF1
2 integral component of presynaptic membrane GO:0099056 9.13 SLC6A4 HTR3A DRD2
3 integral component of postsynaptic membrane GO:0099055 8.8 SLC6A4 HTR3A DRD2

Biological processes related to Social Phobia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.17 TACR1 PTK7 PRL OXT HTR3A HTR1A
2 response to drug GO:0042493 9.88 SLC6A4 DRD2 COMT CAT
3 response to ethanol GO:0045471 9.77 HTR3A DRD2 CAT
4 response to estradiol GO:0032355 9.73 SLC6A4 OXT CAT
5 response to toxic substance GO:0009636 9.71 SLC6A4 DRD2 CAT
6 female pregnancy GO:0007565 9.67 PRL OXT COMT
7 memory GO:0007613 9.65 SLC6A4 OXT CCK
8 vasoconstriction GO:0042310 9.58 SLC6A4 HTR1A
9 dopamine metabolic process GO:0042417 9.55 DRD2 COMT
10 positive regulation of renal sodium excretion GO:0035815 9.52 OXT DRD2
11 grooming behavior GO:0007625 9.51 OXT DRD2
12 neurotransmitter catabolic process GO:0042135 9.46 MAOA COMT
13 catecholamine metabolic process GO:0006584 9.43 MAOA COMT
14 dopamine catabolic process GO:0042420 9.4 MAOA COMT
15 serotonin receptor signaling pathway GO:0007210 9.37 HTR3A HTR1A
16 response to cocaine GO:0042220 9.33 OXT HTR3A DRD2
17 drinking behavior GO:0042756 9.32 OXT DRD2
18 sperm ejaculation GO:0042713 9.26 SLC6A4 OXT
19 response to inactivity GO:0014854 8.96 DRD2 CAT
20 regulation of sensory perception of pain GO:0051930 8.8 OXT COMT CCK

Molecular functions related to Social Phobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.13 PRL OXT CCK
2 serotonin binding GO:0051378 8.8 SLC6A4 HTR3A HTR1A
Sources

Sources for Social Phobia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....